Dental CariesNCT04199897
Effect of a 2-week Sugar Stress on Bacterial Profiles in Whole Saliva
A study testing Succrose rinsing, Probiotic lozenges and xylitol rinsing in people with Dental Caries and Gingivitis, run by University of Copenhagen at 1 site in Denmark.
Trial summary
Dental caries is a non-communicable biofilm-mediated disease affecting both crown and exposed root surfaces in the primary and permanent dentitions. The carious process involves interactions between the biofilm formed on the tooth surface, sugars, salivary and genetic factors. Read more about this study
- Who is it for?
- Ages 18 to 40 yearsHealthy volunteers can take part
- Conditions the study is for
- Dental Caries, Gingivitis
- What is being tested?
- Succrose rinsing, Probiotic lozenges and xylitol rinsing
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 80 participants
- Where
- 1 siteDenmark
- Study dates
- 5 May 2020to 30 Jun 2020
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 40 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- more than 20 own natural teeth
- no chronic systemic diseases affecting salivary functions
- no medication except for contraceptives
- non-smoker
Who cannot join
- treatment requiring oral diseases i.e. dental caries, gingivitis and periodontitis
- systemic antibiotics within the latest 3 months
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Effect of a 2-week Sugar Stress With and Without Probiotic Supplements on Bacterial Profiles in Whole Saliva: A Randomized Controlled Trial
Dental caries is a non-communicable biofilm-mediated disease affecting both crown and exposed root surfaces in the primary and permanent dentitions. The carious process involves interactions between the biofilm formed on the tooth surface, sugars, salivary and genetic factors. Based on more than 100 years of research, there is unequivocal evidence that dietary fermentable carbohydrates (sugars and starch) play a key role in caries initiation and progression. In this context, sucrose deserves special attention; apart from being rapidly converted into acids it is also synthesized into extracellular glucans, fructans and intracellular storage compounds. According to the ecological plaque hypothesis, it is generally accepted that sucrose exposure is fueling and driving the stable and diverse symbiotic oral biofilm to a dysbiotic form with a reduced diversity and overgrowth of acidogenic and acid-tolerating species. Such typical bacterial profiles have demonstrated in subjects with different stages of caries in cross-sectional settings but the timing associated with a sugar provocations is less known. Moreover, the use of probiotic bacteria in adjunct to regular oral care to support biofilm diversity and prevent dental caries has gained momentum in recent years. It has been demonstrated that probiotic supplements can increase salivary pH, and reduce the counts of salivary S. mutans, thereby exert a stabilizing effect on the oral microbiota. In this context, it is of interest to explore whether or not the use of beneficial bacteria can counteract a sugar-driven shift in the salivary microbiota. Another question of interest is to study if the oral biofilm has a colonization memory similar to that of the gastro-intestinal tract and the suggested study design could possibly enlighten this area of research.
Read the detailed description
Objective
The aim of this study is to investigate the bacterial profiles in whole saliva before and after a 2-week sugar provocation with and without probiotic supplements in healthy young adults. A second aim is to study the bacterial profiles 3 weeks after the termination of the sugar stress. The null hypothesis are:
- Sucrose-induced stress does not affect the bacterial profiles in whole saliva compared with stress induced by a non-fermentable pentitol (xylitol)
- The intake of lactobacilli-derived probiotic bacteria does not affect the sugar-induced changes in the bacterial profiles in whole saliva when compared with placebo
- The bacterial profiles in saliva do not differ from baseline 3 weeks after the termination of the intervention.
Material The study group will consist of 80 young adults with uncompromised oral health that volunteer after informed consent. The inclusion criteria are i) over 18 years with more than 20 own natural teeth, ii) no chronic systemic diseases affecting salivary functions, iii) no medication except for contraceptives, and iv) being a non-smoker. The project will be submitted for ethical approval.
Study design The study will employ a randomized triple-blind, placebo controlled design with four parallel arms as shown in Figure 1. The group allocation will be arranged through computer-generated envelopes and concealed for all parts (subjects, investigators, laboratory staff). After the baseline registration (Day 0), the participants are asked to rinse their mouth with 10 mL of a sucrose- or xylitol-containing solution every second hour (7-8 times per day) during 14 days (day 14). The solution should be "swished" around and between the teeth for at least 30 seconds and then spitted out. No after-rinsing with water is allowed. In addition, the subjects are provided with tablets containing either probiotic lactobacilli or placebo for daily use during the 14-day rinsing period. The participants will be thoroughly instructed to maintain their normal eating and drinking habits as well as their daily oral hygiene procedures.
Intervention - probiotics and placebo The active and placebo lozenges for the 14-day intervention period will be distributed to the participants after baseline examination and sampling. The active lozenges contain two strains of probiotic bacteria; Lactobacillus rhamnosus PB01 (DSM 14869) and Lactobacillus curvatus EB10 (DSM 32307) at a concentration of 109 colony forming units each. The tablets have previously been used in a randomized controlled trial with gingival inflammation and microbial endpoints (Keller et al., 2018). The full composition is shown in Appendix X. The placebo lozenges have an identical composition, except for the bacteria, with the same size and taste. The participants are instructed to let one tablet slowly dissolve in the mouth two times per day (morning, evening) after regular tooth brushing. They are also required to keep a daily logbook covering the sugar rinses and tablet intakes and to return non-consumed tablet at the first follow-up. The sugar rinses will be prepared and distributed in non-marked bottles and the participants will be supplied with a dose spoon indicating 10 mL. The participants will also be given a standardized fluoride toothpaste for use during the entire study. An independent monitor at Copenhagen University will guarantee the allocation concealment.
Clinical examination and saliva samplings At baseline, a clinical examination is performed by one experienced and calibrated dentist. No radiographs are exposed. The following variables are registered: a) caries experience, expressed as decayed, missed and filled teeth (DMFT), b) the amount of supragingival plaque (s-PI), c) the level of gingival inflammation (s-GI), and d) bleeding-on-probing (s-BOP). The PI, GI and BOP will be scored in a simplified manner on six pre-selected teeth and re-evaluated at the follow-ups after 14 and 35 days. Stimulated whole saliva samples (approximately 1.0 mL) will be collected at baseline and after 14 and 35 days in a standardized way by one trained investigator. All samples are stored at -80°C until further processing.
Laboratory procedures The DNA will be extracted using a Pathogen_Universal_200 protocol (Roche) in accordance with the manufacturer's guidelines at the Institute for Inflammatory Research, Rigshospitalet, København, Danmark. The profiles of the salivary microbiome will be analysed with Next Generation Sequencing (NGS) and qPCR as preciously described (Keller et al., 2018).
Endpoints Salivary bacterial profiles will be analyzed by means of the Human Oral Microbe Identification using Next Generation Sequencing (HOMINGS) in co-operation with the Costerton Center at University of Copenhagen. Secondary endpoints are simplified plaque index (PI), gingival index (GI) and bleeding-on-probing (BOP) as scored after 15 and 35 days.
Statistical methods All data will be checked for normality and processed with the IBM-SPSS software. Clinical data are compared using the Freidman test with Dunn's comparison. Relative abundance of bacterial DNA reads are compared between groups of samples at genus and species level using the Kruskal-Wallis and Mann-Whitney tests with Benjamini-Hochberg correction for multiple dependent analyses. P-values less than 0.05 will be considered statistically significant.
- Conditions
- Dental Caries, Gingivitis
- Being tested
- Succrose rinsing, Probiotic lozenges, xylitol rinsing, Placebo tablets
- Keywords
- Dental Caries, Salivary microbiota, Probiotics
- Medical subject headings
- Dental Caries, Gingivitis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Succrose rinsingDietary supplement
Sucrose rinsing 7-8 times a day for 14 days
Probiotic lozengesDietary supplement
Probiotic lozenges 2 times a day for 35 days
xylitol rinsingOther
Xylitol rinsing 7-8 times a day for 14 days
Placebo tabletsOther
Placebo lozenges 2 times a day for 35 days
| Study group | Role | What they receive |
|---|---|---|
| Intervention group (sucrose + probiotics) | Experimental | Sucrose rinsing 8 times a day for 14 days Probiotic lozenges 2 times a day for 25 days Receives: Dietary Supplement: Succrose rinsing; Dietary Supplement: Probiotic lozenges |
| Intervention group (sucrose + placebo | Active comparator | Sucrose rinsing 8 times a day for 14 days Placebo lozenges 2 times a day for 25 days Receives: Dietary Supplement: Succrose rinsing; Other: Placebo tablets |
| Control group (xylitol + probiotics) | Placebo comparator | Xylitol rinsing 8 times a day for 14 days Probiotic lozenges 2 times a day for 25 days Receives: Dietary Supplement: Probiotic lozenges; Other: xylitol rinsing |
| Control group (xylitol + placebo | Placebo comparator | Xylitol rinsing 8 times a day for 14 days Placebo lozenges 2 times a day for 25 days Receives: Other: xylitol rinsing; Other: Placebo tablets |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in microbial diversity of salivary microbiota
alpha-diversity (shannon-index)
Measured: Baseline alpha-diversity vs. alpha-diversity at day 35
Secondary outcomes (2)
Change in supragingival biofilm level
Plaque-index (% of sites with visible plaque)
Measured: Baseline plaque-index vs. plaque-index day 35
Change in gingival bleeding
Bleeding-index (%sites with bleeding)
Measured: Baseline bleeding-index vs. bleeding-index day 35
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted16 Dec 2019
- Study start5 May 2020
- Primary completion30 Jun 2020
- Study completion30 Jun 2020
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Dental CariesStudies of the same condition, open and under way.
- More trials run by University of CopenhagenThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- The study will employ a randomized triple-blind, placebo controlled design.
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 80 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Copenhagen
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Daniel Belstrøm, DDS, PhD, University of Copenhagen
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04199897
- Sponsor's protocol ID
- UCPH_OI_004
- Status last verified
- Oct 2021
- First submitted
- 9 Dec 2019
- Last updated
- 15 Oct 2021
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 15 Oct 2021. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effect of a 2-week Sugar Stress With and Without Probiotic Supplements on Bacterial Profiles in Whole Saliva: A Randomized Controlled Trial
- ClinicalTrials.gov ID
- NCT04199897
- Acronym / sponsor ID
- UCPH_OI_004
- Conditions
- Dental Caries, Gingivitis
- Keywords
- Dental Caries, Salivary microbiota, Probiotics
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 80 participants (actual)
- Lead sponsor
- University of CopenhagenUniversity, hospital or other
- Study start
- 5 May 2020 (actual)
- Primary completion
- 30 Jun 2020 (actual)
- Study completion
- 30 Jun 2020 (actual)
- First posted
- 16 Dec 2019 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Dental caries is a non-communicable biofilm-mediated disease affecting both crown and exposed root surfaces in the primary and permanent dentitions. The carious process involves interactions between the biofilm formed on the tooth surface, sugars, salivary and genetic factors. Based on more than 100 years of research, there is unequivocal evidence that dietary fermentable carbohydrates (sugars and starch) play a key role in caries initiation and progression. In this context, sucrose deserves special attention; apart from being rapidly converted into acids it is also synthesized into extracellular glucans, fructans and intracellular storage compounds. According to the ecological plaque hypothesis, it is generally accepted that sucrose exposure is fueling and driving the stable and diverse symbiotic oral biofilm to a dysbiotic form with a reduced diversity and overgrowth of acidogenic and acid-tolerating species. Such typical bacterial profiles have demonstrated in subjects with different stages of caries in cross-sectional settings but the timing associated with a sugar provocations is less known. Moreover, the use of probiotic bacteria in adjunct to regular oral care to support biofilm diversity and prevent dental caries has gained momentum in recent years. It has been demonstrated that probiotic supplements can increase salivary pH, and reduce the counts of salivary S. mutans, thereby exert a stabilizing effect on the oral microbiota. In this context, it is of interest to explore whether or not the use of beneficial bacteria can counteract a sugar-driven shift in the salivary microbiota. Another question of interest is to study if the oral biofilm has a colonization memory similar to that of the gastro-intestinal tract and the suggested study design could possibly enlighten this area of research.
Detailed description
Objective
The aim of this study is to investigate the bacterial profiles in whole saliva before and after a 2-week sugar provocation with and without probiotic supplements in healthy young adults. A second aim is to study the bacterial profiles 3 weeks after the termination of the sugar stress. The null hypothesis are:
- Sucrose-induced stress does not affect the bacterial profiles in whole saliva compared with stress induced by a non-fermentable pentitol (xylitol)
- The intake of lactobacilli-derived probiotic bacteria does not affect the sugar-induced changes in the bacterial profiles in whole saliva when compared with placebo
- The bacterial profiles in saliva do not differ from baseline 3 weeks after the termination of the intervention.
Material The study group will consist of 80 young adults with uncompromised oral health that volunteer after informed consent. The inclusion criteria are i) over 18 years with more than 20 own natural teeth, ii) no chronic systemic diseases affecting salivary functions, iii) no medication except for contraceptives, and iv) being a non-smoker. The project will be submitted for ethical approval.
Study design The study will employ a randomized triple-blind, placebo controlled design with four parallel arms as shown in Figure 1. The group allocation will be arranged through computer-generated envelopes and concealed for all parts (subjects, investigators, laboratory staff). After the baseline registration (Day 0), the participants are asked to rinse their mouth with 10 mL of a sucrose- or xylitol-containing solution every second hour (7-8 times per day) during 14 days (day 14). The solution should be "swished" around and between the teeth for at least 30 seconds and then spitted out. No after-rinsing with water is allowed. In addition, the subjects are provided with tablets containing either probiotic lactobacilli or placebo for daily use during the 14-day rinsing period. The participants will be thoroughly instructed to maintain their normal eating and drinking habits as well as their daily oral hygiene procedures.
Intervention - probiotics and placebo The active and placebo lozenges for the 14-day intervention period will be distributed to the participants after baseline examination and sampling. The active lozenges contain two strains of probiotic bacteria; Lactobacillus rhamnosus PB01 (DSM 14869) and Lactobacillus curvatus EB10 (DSM 32307) at a concentration of 109 colony forming units each. The tablets have previously been used in a randomized controlled trial with gingival inflammation and microbial endpoints (Keller et al., 2018). The full composition is shown in Appendix X. The placebo lozenges have an identical composition, except for the bacteria, with the same size and taste. The participants are instructed to let one tablet slowly dissolve in the mouth two times per day (morning, evening) after regular tooth brushing. They are also required to keep a daily logbook covering the sugar rinses and tablet intakes and to return non-consumed tablet at the first follow-up. The sugar rinses will be prepared and distributed in non-marked bottles and the participants will be supplied with a dose spoon indicating 10 mL. The participants will also be given a standardized fluoride toothpaste for use during the entire study. An independent monitor at Copenhagen University will guarantee the allocation concealment.
Clinical examination and saliva samplings At baseline, a clinical examination is performed by one experienced and calibrated dentist. No radiographs are exposed. The following variables are registered: a) caries experience, expressed as decayed, missed and filled teeth (DMFT), b) the amount of supragingival plaque (s-PI), c) the level of gingival inflammation (s-GI), and d) bleeding-on-probing (s-BOP). The PI, GI and BOP will be scored in a simplified manner on six pre-selected teeth and re-evaluated at the follow-ups after 14 and 35 days. Stimulated whole saliva samples (approximately 1.0 mL) will be collected at baseline and after 14 and 35 days in a standardized way by one trained investigator. All samples are stored at -80°C until further processing.
Laboratory procedures The DNA will be extracted using a Pathogen_Universal_200 protocol (Roche) in accordance with the manufacturer's guidelines at the Institute for Inflammatory Research, Rigshospitalet, København, Danmark. The profiles of the salivary microbiome will be analysed with Next Generation Sequencing (NGS) and qPCR as preciously described (Keller et al., 2018).
Endpoints Salivary bacterial profiles will be analyzed by means of the Human Oral Microbe Identification using Next Generation Sequencing (HOMINGS) in co-operation with the Costerton Center at University of Copenhagen. Secondary endpoints are simplified plaque index (PI), gingival index (GI) and bleeding-on-probing (BOP) as scored after 15 and 35 days.
Statistical methods All data will be checked for normality and processed with the IBM-SPSS software. Clinical data are compared using the Freidman test with Dunn's comparison. Relative abundance of bacterial DNA reads are compared between groups of samples at genus and species level using the Kruskal-Wallis and Mann-Whitney tests with Benjamini-Hochberg correction for multiple dependent analyses. P-values less than 0.05 will be considered statistically significant.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 4
- Model description
- The study will employ a randomized triple-blind, placebo controlled design.
| Arm | Type | Receives |
|---|---|---|
| Intervention group (sucrose + probiotics) | Experimental | Dietary Supplement: Succrose rinsing, Dietary Supplement: Probiotic lozengesSucrose rinsing 8 times a day for 14 days Probiotic lozenges 2 times a day for 25 days |
| Intervention group (sucrose + placebo | Active comparator | Dietary Supplement: Succrose rinsing, Other: Placebo tabletsSucrose rinsing 8 times a day for 14 days Placebo lozenges 2 times a day for 25 days |
| Control group (xylitol + probiotics) | Placebo comparator | Dietary Supplement: Probiotic lozenges, Other: xylitol rinsingXylitol rinsing 8 times a day for 14 days Probiotic lozenges 2 times a day for 25 days |
| Control group (xylitol + placebo | Placebo comparator | Other: xylitol rinsing, Other: Placebo tabletsXylitol rinsing 8 times a day for 14 days Placebo lozenges 2 times a day for 25 days |
Who may qualify
- Ages
- 18 to 40 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (4 listed)
- more than 20 own natural teeth
- no chronic systemic diseases affecting salivary functions
- no medication except for contraceptives
- non-smoker
Key exclusion criteria (2 listed)
- treatment requiring oral diseases i.e. dental caries, gingivitis and periodontitis
- systemic antibiotics within the latest 3 months
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Succrose rinsingSucrose rinsing 7-8 times a day for 14 days | Dietary supplement | Intervention group (sucrose + placebo, Intervention group (sucrose + probiotics) |
| Probiotic lozengesProbiotic lozenges 2 times a day for 35 days | Dietary supplement | Control group (xylitol + probiotics), Intervention group (sucrose + probiotics) |
| xylitol rinsingXylitol rinsing 7-8 times a day for 14 days | Other | Control group (xylitol + placebo, Control group (xylitol + probiotics) |
| Placebo tabletsPlacebo lozenges 2 times a day for 35 days | Other | Control group (xylitol + placebo, Intervention group (sucrose + placebo |
Primary outcome
Change in microbial diversity of salivary microbiota
Time frame: Baseline alpha-diversity vs. alpha-diversity at day 35
alpha-diversity (shannon-index)
2 secondary outcomes
Change in supragingival biofilm level
Time frame: Baseline plaque-index vs. plaque-index day 35
Change in gingival bleeding
Time frame: Baseline bleeding-index vs. bleeding-index day 35
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 15 Oct 2021.
- Individual participant dataSharing planned: No
Related trials for Dental Caries
Active, not recruiting
Clinical Evaluation of a New Dual-cure Universal Adhesive
Class I Dental Restorations, Class II Dental Restorations
Not yet recruiting
Safety of Intraosseous Anaesthesia in Children With Haemophilia
Haemophilia A, Haemophilia B
Not yet recruiting
Clinical and Radiographic Evaluation of Silver Diamine Fluoride Versus Light-Cured Silver Diamine Fluoride in Carious Primary Molars
Dental Caries
Not yet recruiting
Clinical Performance of CAD/CAM Hard Hybrid Ceramic Inlays Versus Resin Composite Inlays in Vital Molars With Extensive Occluso-Proximal Cavities
Dental Caries, Cavity, Dental
Not yet recruiting
Effect of Xylitol- Versus Erythritol-Sweetened Mints on Plaque ATP-Bioluminescence Readings
Dental Caries, Dental Plaque
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Succrose rinsing, Probiotic lozenges and xylitol rinsing in people with Dental Caries and Gingivitis, run by University of Copenhagen at 1 site in Denmark.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 15 Oct 2021. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Denmark. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in microbial diversity of salivary microbiota (time frame: Baseline alpha-diversity vs. alpha-diversity at day 35). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Oct 2021.